Tumor Biology

, Volume 34, Issue 6, pp 3509–3517 | Cite as

Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies

  • Dan Wang
  • Omar Israel Vélez de-la-Paz
  • Jun-Xia Zhai
  • Dian-Wu Liu
Research Article


There were some case–control studies, nested case–control studies, and cohort studies with controversial results on the association between serum 25-hydroxyvitamin D [25(OH)D] and breast cancer risk. Case–control studies are prone to selection bias, which limit the strength and quality of the evidence. To overcome the shortcoming of the case–control studies, the meta-analysis of prospective studies including nested case–control studies and cohort studies was conducted. PubMed, Embase, and Web of Science databases were searched, and the last retrieval date was March 24, 2013. For the highest versus the lowest level of serum 25(OH)D, the relative risks (RRs) and its 95 % confidence intervals (CIs) from each study were used to estimate summary RR and its 95 % CI. Subgroup analyses by geographic region, menopausal status, and adjusted status of RR were also performed, respectively. A dose–response association between serum 25(OH)D concentration and breast cancer risk was assessed. Fourteen articles with 9,110 breast cancer cases and 16,244 controls were included in the meta-analysis. Overall, serum 25(OH)D levels were inversely significantly associated with breast cancer risk (RR = 0.845, 95 % CI = 0.750–0.951). Inversely statistically significant associations were observed in North American studies, postmenopausal women, and studies with adjusted and unadjusted RR, respectively. No statistically significant associations were observed in European studies and premenopausal women, respectively. Dose–response analysis showed that every 10 ng/mL increment in serum 25(OH)D concentration was associated with a significant 3.2 % reduction in breast cancer risk. This meta-analysis provides evidence of a significantly inverse association between serum 25(OH)D concentration and breast cancer risk.


Vitamin D 25-Hydroxyvitamin D Breast cancer risk Meta-analysis 



25-Hydroxyvitamin D


1,25-Dihydroxyvitamin D




Relative risk


Confidence interval


Standard error


Vitamin D receptor



This work was supported by the grants from the National Natural Science Foundation of China (no. 30972516), Natural Science Foundation of Hebei Province (no. C2010000481), and Hebei Province Health Bureau Foundation (no. 20090004).

Conflicts of interest



  1. 1.
    Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9:941–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys. 2012;523:107–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96:252–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Essebag V, Genest Jr J, Suissa S, Pilote L. The nested case–control study in cardiology. Am Heart J. 2003;146:581–90.Google Scholar
  6. 6.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRefGoogle Scholar
  7. 7.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  8. 8.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  9. 9.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenland S, Longnecker MP. Methods for trend estimation from summarized dose–response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–9.PubMedGoogle Scholar
  11. 11.
    Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes Control. 2011;22:319–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1991–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100:1581–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008;17:889–94.PubMedCrossRefGoogle Scholar
  15. 15.
    McCullough ML, Stevens VL, Patel R, et al. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009;11:R64.PubMedCrossRefGoogle Scholar
  16. 16.
    Rejnmark L, Tietze A, Vestergaard P, et al. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2009;18:2655–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk—a prospective nested case–control study. Int J Cancer. 2010;127:2159–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case–control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010;19:2341–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res. 2011;13:R50.PubMedCrossRefGoogle Scholar
  20. 20.
    Eliassen AH, Tworoger SS, Bertone-Johnson E, Rosner B, Willett WC, Hankinson SE. Circulating vitamin D and breast cancer risk: repeated exposure assessment and 18 years of follow-up in the Nurses’ Health Study. Cancer Res. 2011;71:4633.CrossRefGoogle Scholar
  21. 21.
    Amir E, Cecchini RS, Ganz PA, et al. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat. 2012;133:1077–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol. 2012;175:673–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Mohr SB, Gorham ED, Alcaraz JE, et al. Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum. Cancer Causes Control. 2013;24:495–504.PubMedCrossRefGoogle Scholar
  24. 24.
    Ordonez-Mena JM, Schottker B, Haug U, et al. Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013;22:905–16.PubMedCrossRefGoogle Scholar
  25. 25.
    Green AK, Hankinson SE, Bertone-Johnson ER, Tamimi RM. Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. Int J Cancer. 2010;127:667–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992;44:693–702.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen P, Li M, Gu X, et al. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case–control study and meta-analysis of the observational studies. PLoS One. 2013;8:e49312.PubMedCrossRefGoogle Scholar
  28. 28.
    Mohr SB, Gorham ED, Alcaraz JE, et al. Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011;31:2939–48.PubMedGoogle Scholar
  29. 29.
    Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46:2196–205.PubMedCrossRefGoogle Scholar
  30. 30.
    Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128:1414–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121:469–77.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Dan Wang
    • 1
    • 2
  • Omar Israel Vélez de-la-Paz
    • 3
    • 4
  • Jun-Xia Zhai
    • 5
  • Dian-Wu Liu
    • 1
  1. 1.Department of Epidemiology and Biostatistics, School of Public HealthHebei Medical UniversityShijiazhuangChina
  2. 2.LibraryHebei Medical UniversityShijiazhuangChina
  3. 3.Department of Foreign LanguagesHebei Normal UniversityShijiazhuangChina
  4. 4.School of International EducationWestern Campus, Hebei Medical UniversityShijiazhuangChina
  5. 5.Department of Novelty RetrievalInstitute of Hebei Medical InformationShijiazhuangChina

Personalised recommendations